(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Vote in favor of the bloom plan that adds a bit of excellence to your life! - 2Renewables cover over 50% of German electricity consumption in Q1
- 3Tech for Efficiency: Applications and Apparatuses to Accomplish More
- 4Two IDF officers, civilian face indictment in alleged Gaza aid-truck smuggling scheme
- 5Anger as German family business group opens talks with far-right AfD
- Russia earning billions from Hormuz blockade, German trade body says
- Some Americans say they'll go without health insurance as ACA rates spike
- Child influencers helped power a booming industry. It's time for a reckoning.
- The most effective method to Offset Album Rates with Liquidity Needs
- Russia confirms 16 Cameroonian soldiers killed in Ukraine war
- Eli Lilly to build $6 billion Alabama plant as part of US manufacturing push
- 1st-ever disease gene fix, Alzheimer's blood test: 7 medical breakthroughs in 2025
- Sound and Delightful: 12 Nutritious Smoothie Recipes
- Merz: 80% of Syrians in Germany should return in three years
